A recent article titled “Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension”, published in the New England Journal of Medicine, reports on the results of a multicenter, double-blind, phase 3 trial in which adults with pulmonary arterial hypertension (functional class II or III) who were receiving stable background therapy were randomly assigned in a 1:1 ratio to receive subcutaneous sotatercept or placebo every 3 weeks. The findings revealed that in patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. Study Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988
An abstract of the article is available at this link on the New England Journal of Medicine web page.
Marius M. Hoeper, M.D., David B. Badesch, M.D., H. Ardeschir Ghofrani, M.D., J. Simon R. Gibbs, M.D., Mardi Gomberg-Maitland, M.D., Vallerie V. McLaughlin, M.D., Ioana R. Preston, M.D., Rogerio Souza, M.D., Ph.D., Aaron B. Waxman, M.D., Ph.D., Ekkehard Grünig, M.D., Grzegorz Kopeć, M.D., Ph.D., Gisela Meyer, M.D., et al., for the STELLAR Trial Investigators*, April 20, 2023, N Engl J Med 2023; 388:1478-1490, DOI: 10.1056/NEJMoa2213558